Abstract
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
New Emirates Medical Journal
Title:Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis
Volume: 1 Issue: 2
Author(s): Mohamed Abuzakouk*, Omar Ghorab, Safieeldin Ghazala and Anastasios Hantzakos
Affiliation:
- Department of Allergy and Immunology, Cleveland Clinic Abu Dhabi, Abu Dhabi,United Arab Emirates
Keywords: Mepolizumab, Nasal polyps, Olfaction disorders, Sinusitis, Paranasal sinus diseases, Rhinosinusitis.
Abstract:
Introduction: To date, there is no permanent medical treatment for nasal polyposis and loss of sense of smell. Mepolizumab is an anti-IL-5 monoclonal antibody approved for the treatment of patients with eosinophilic asthma. It has been suggested that it is capable of improving olfactory dysfunction in patients with chronic rhinosinusitis and nasal polyposis.
Case: We present a 35-year-old Emirati male with progressively worsening rhinosinusitis, recurring nasal polyps and total loss of sense of smell. He was treated with oral steroids, normal saline nasal sprays and all available topical steroids without significant or permanent symptom relief. He was commenced on Mepolizumab, and upon receiving the 4th dose, he reported full recovery of his sense of smell.
Conclusion: Mepolizumab appears to be very effective in treating loss of sense of smell. Further studies should be conducted to assess the efficacy and effectiveness of Mepolizumab in patients with chronic rhinosinusitis, nasal polyposis and anosmia.
Export Options
About this article
Cite this article as:
Abuzakouk Mohamed *, Ghorab Omar , Ghazala Safieeldin and Hantzakos Anastasios , Recovery of Sense of Smell by Mepolizumab in a Patient with Chronic Rhinosinusitis and Nasal Polyposis, New Emirates Medical Journal 2020; 1 (2) . https://dx.doi.org/10.2174/0250688202002022006
DOI https://dx.doi.org/10.2174/0250688202002022006 |
Print ISSN 0250-6882 |
Publisher Name Bentham Science Publisher |
Online ISSN 0250-6882 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ether Glycerophospholipids and Their Potential as Therapeutic Agents
Current Organic Chemistry Probiotics as an Alternative Strategy for Prevention and Treatment of Human Diseases: A Review
Inflammation & Allergy - Drug Targets (Discontinued) The Pharmacological Pathways of GnRH Mediating the Inhibition of Mammary Tumours: Implications in Humans and Domestic Animals
Current Medicinal Chemistry Alteration of Isocitrate Dehydrogenase Following Acute Ischemic Injury as a Means to Improve Cellular Energetic Status in Neuroadaptation
CNS & Neurological Disorders - Drug Targets Regulation of Cytokine Production by γδ T Cells
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Use of Thiazolidinediones and Risk of Bladder Cancer: Disease or Drugs?
Current Drug Safety Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry (Phospho)lipid-based Nanosystems for Skin Administration
Current Pharmaceutical Design There is no Failure, Only Discovery—the Year Ahead for CARving New Paths
Current Alzheimer Research Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry Editorial: Medical Science Beyond Formal Institutional Boundaries
Inflammation & Allergy - Drug Targets (Discontinued) Artificial Hematopoietic Stem Cell Niche: Bioscaffolds to Microfluidics to Mathematical Simulations
Current Topics in Medicinal Chemistry Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer
Mini-Reviews in Medicinal Chemistry Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Investigation of 5-HT<sub>3A</sub> Receptor Gene Expression in Peripheral Blood Mononuclear Cells of Individuals who had been Exposed to Air Pollution
Inflammation & Allergy - Drug Targets (Discontinued) Natural Products and Transforming Growth Factor-beta (TGF-β) Signaling in Cancer Development and Progression
Current Cancer Drug Targets Heart Failure in Chronic Myocarditis: A Role for microRNAs?
Current Genomics Current Advances in Retroviral Gene Therapy
Current Gene Therapy Editorial (Thematic Issue: Lipidic Nano-carrier Delivery of “Big” Molecules)
Current Pharmaceutical Biotechnology Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs